Article Text

Download PDFPDF
Cost minimisation of RSV prevention with palivizumab
  1. S Wills,
  2. J H Simpson,
  3. J Coutts
  1. Queen Mother’s Hospital, Glasgow, UK
  1. Correspondence to:
    Dr J H Simpson
    Paediatric Department, Queen Mother’s Hospital, Glasgow, UK; judith.simpson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

An outpatient respiratory syncytial virus (RSV) prophylaxis programme has been provided in Glasgow since 1999. Initially only high risk neonates were included but subsequently patients with congenital heart disease, congenital lung abnormalities, and other complex histories have been offered prophylaxis. Early attempts to minimise drug wastage via a buddy system were unsuccessful, with only a 1.4% cost saving in 2003–04. During the 2004–05 RSV season we aimed to strictly coordinate the delivery of effective prophylaxis while minimising drug costs through patient cohorting and …

View Full Text


  • Competing interests: none declared